Quadrivalent meningococcal vaccine became available in the United States in 2005 which offers protection against ACWY strains of meningococcal meningitis or septicemia.

In 2014-15, meningococcal serogroup B (MenB) vaccines became available. Young people 16-23 years of age who are determined to be at risk for this illness should be offered this new product. A recent study in where the investigators utilized data from the National Notifiable Diseases Surveillance System from 45 states. Confirmed and probable cases among 18- to 24-year-olds that occurred between 2014 and 2016 were included in the study. The result: overall incidence of meningococcal disease is low in college-aged young adults but appear to be at increased risk for this life-threatening infection primarily due to serogroup B.

Read full story here